Navigation Links
FDA Puts Partial Hold on Avandia Safety Study
Date:7/21/2010

WEDNESDAY, July 21 (HealthDay News) -- No new patients will be permitted to enroll in a safety study of the controversial diabetes drug Avandia until further notice, the U.S. Food and Drug Administration announced Wednesday.

But under the partial clinical trial hold, those patients already enrolled in the TIDE (Thiazolidinedione Intervention With Vitamin D Evaluation) trial will be allowed to continue to participate, the agency said in a news release.

An FDA advisory panel last week ruled that Avandia (rosiglitazone) does boost users' heart risks, but it also decided that the drug should stay on the market because there's no definitive evidence of an increased risk.

The FDA said Wednesday that it is evaluating available data on Avandia's safety and the discussions from last week's advisory panel meeting. When the review is complete, the agency will inform the public about the findings and what they mean for the drug's status and the TIDE trial.

GlaxoSmithKline, which makes Avandia, was told by the FDA to update researchers, institutional review boards and ethics committees involved in the TIDE trial about new safety information presented at the FDA advisory panel meeting. That information can be used to update informed consent information for people already enrolled in the TIDE trial, the FDA said.

GSK agreed to conduct the TIDE trial in 2007 after concerns about the safety of Avandia first became public. The goal of the trial is to determine whether Avandia poses greater heart risks than a competing drug called Actos.

In a news release, the drug company confirmed that it will suspend enrollment of new patients in the TIDE trial and send a summary of recent safety data and a summary of the FDA advisory panel meeting to all TIDE researchers and institutional review boards.

"This pause in enrollment will give clinical trial investigators and patients time to learn about the data presented to the FD
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. Lacosamide validated as promising therapy for uncontrolled partial-onset seizures
2. Deep brain stimulation reduces epileptic seizures in patients with refractory partial and secondarily generalized seizures
3. Study shows partial lung removal favorable over full removal as treatment for lung cancer
4. Hip surgery success partially predicted by number of other existing conditions
5. Diabetes Drugs Avandia, Actos Tied to Fractures in Women
6. Remove Diabetes Drug Avandia From Market: FDA Reports
7. Remove Diabetes Drug Avandia From Market: FDA Documents
8. FDA Says It Hasnt Decided Whether to Pull Diabetes Drug Avandia Off the Market
9. FDA: No Decision on Whether to Pull Diabetes Drug Avandia Off the Market
10. Maher Law Firm Warns Avandia Users - NY Times Reports - FDA Recommends Recall of Avandia
11. Diabetes Drug Avandia Ups Heart Risk, Reviews Conclude
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Puts Partial Hold on Avandia Safety Study
(Date:7/2/2015)... VA (PRWEB) , ... July 02, 2015 , ... sweetFrog ... Texas. The opening is now the 19th sweetFrog store located in the Lone Star ... list of fastest growing companies in 2014. , The store, which opened July 1 ...
(Date:7/2/2015)... ... ... swing, Americans are flocking to Canada’s many lakes to reel in their fair share of ... it’s easy to understand why. From the Pacific Northwest Coast of British Columbia to the ... huge industry, and Americans make up the vast majority of anglers from outside of Canada. ...
(Date:7/2/2015)... ... July 02, 2015 , ... Global leader and compression innovator, SIGVARIS ... for men. , For style that’s quick on its feet, men will love ... great news for men everywhere because a simple change in socks can dramatically help ...
(Date:7/2/2015)... TX (PRWEB) , ... July ... ... pressure wound therapy (NPWT) - pipeline review 2015” provides comprehensive information on ... of development. Complete report on negative pressure wound therapy (NPWT) with 22 ...
(Date:7/2/2015)... ... July 02, 2015 , ... Breakthrough technologies ... pain treatment. Dr. Lev Kalika, founder of New York Dynamic Neuromuscular Rehabilitation ... on the conservative treatment of back, hip, knee and shoulder pain as well ...
Breaking Medicine News(10 mins):Health News:sweetFrog Expands Texas Footprint with Location in Canton 2Health News:SIGVARIS Kicks Up Its Style for Men with the Launch of MIDTOWN MICROFIBER in a Dark Navy Stripe Pattern 2Health News:SIGVARIS Kicks Up Its Style for Men with the Launch of MIDTOWN MICROFIBER in a Dark Navy Stripe Pattern 3Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Negative Pressure Wound Therapy (System, Wound Care, Tissue Cooling NPWT) Pipeline Review 2015 Market Research Report Available at RnRMarketResearch.com 4Health News:Breakthrough Technologies for Carpal Tunnel Treatment in New York City 2Health News:Breakthrough Technologies for Carpal Tunnel Treatment in New York City 3Health News:Breakthrough Technologies for Carpal Tunnel Treatment in New York City 4
... Calif., March 31 Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ... financing facility under which it may sell up to ... Ltd. over a,24-month period. Alexza is not obligated to ... to enter into and consummate other equity and,debt financing ...
... occur , , MONDAY, March 31 (HealthDay News) -- Cerebral ... from red blood cells that have leaked out of ... over age 60 than previously believed, according to a ... higher overall prevalence of cerebral microbleeds compared to other ...
... WILMINGTON, N.C., March 31 PPD, Inc. (Nasdaq:,PPDI) ... as executive,vice president of global clinical development. In ... company,s Phase II-IV operations in,North America; Latin America; ... "Mike Wilkinson brings an exceptional resume with strong ...
... A Saint Louis University cardiologist called upon the U.S. ... strong warning it recently placed on a diagnostic tool, ... life-threatening cardiac events. , In October 2007, the ... agents, which are used to improve the quality of ...
... following was,issued today by the National Press Club:, National ... 2:00 p.m., National Press Club (Broadcast Center), ... will discuss,Quality as a Path to Improving the Cost of ... patient safety and health care products and,services company, R. Kerry ...
... By Will Arnett, Matthew Broderick, Steve Carell, Stephen, ... Kevin James,Conan O,Brien, Rosie O,Donnell, Amy Poehler, Adam Sandler, ... The Insult Comic Dog And Many More To Be ... announced today that,Kelsey Grammer, Ben Stiller, Grammy Award-winning band ...
Cached Medicine News:Health News:Alexza Secures $50 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd. 2Health News:Alexza Secures $50 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd. 3Health News:Alexza Secures $50 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd. 4Health News:Small Brain Lesions More Common Than Thought in Those Over 60 2Health News:PPD Names Mike Wilkinson Executive Vice President of Global Clinical Development 2Health News:PPD Names Mike Wilkinson Executive Vice President of Global Clinical Development 3Health News:New research shows benefits of ultrasound contrast agents outweigh potential risk to heart patients 2Health News:New research shows benefits of ultrasound contrast agents outweigh potential risk to heart patients 3Health News:Kelsey Grammer, Ben Stiller, Maroon 5 and The Roots Added to COMEDY CENTRAL's(R) Live On-air Charity Special 'Night of Too Many Stars: An Overbooked Concert for Autism Education' Hosted by Jon Stewart on Sunday April 13, at 8 p.m. ET 2
(Date:7/2/2015)... 2015  New product launches are critical events for ... educating thought leaders about new products, Medical Affairs is ... well a new therapy performs at launch. ... consulting leader Best Practices, LLC, critical aspects of launch ... are early stage thought leader (TL) interaction, successful TL ...
(Date:7/2/2015)... 2015 According to a new market ... Stimulation, Spinal Cord Stimulation, Transcranial Magnetic Stimulation), Application (Depression, Parkinson,s, ... 2020", published by MarketsandMarkets, the global Neuromodulation Market is estimated ... $6.20 Billion by 2020, at a CAGR of 11.2% during ... 4 market data T ables and ...
(Date:7/2/2015)... , July 2, 2015 Numotion,s Board ... Officer announced that Tamas Feitel has joined ... joins Numotion after a highly successful 18 year career ... roles driving strategy, profitability, and productivity to result in ... recent position was Chief Financial Officer for GE Healthcare ...
Breaking Medicine Technology:Medical Affairs Role in Thought Leader Education is Key Success Factor for New Product Launches in the Pharmaceutical Industry 2Neuromodulation Market Worth $6.20 Billion by 2020 2Neuromodulation Market Worth $6.20 Billion by 2020 3Neuromodulation Market Worth $6.20 Billion by 2020 4Numotion Names Tamas Feitel Chief Financial Officer 2
... Vancouver Radiologists, P.C., a full-spectrum provider of diagnostic ... greater Vancouver, Wash., and Portland, Ore., areas, has ... use of MedInformatix Inc.,s Radiology Information System ... three-location practice to control from a single platform ...
... CareFusion (NYSE: CFN ), ... Officer Dwight Winstead will leave the company on June 30. ... separated from Cardinal Health on Sept. 1, 2009, during which ... for the company,s business segments. He joined Cardinal Health in ...
Cached Medicine Technology:Vancouver Radiologists Leverages MedInformatix RIS as Practice Management Hub, Data Mining Tool to Improve Workflow and Enhance Efficiencies 2Vancouver Radiologists Leverages MedInformatix RIS as Practice Management Hub, Data Mining Tool to Improve Workflow and Enhance Efficiencies 3Vancouver Radiologists Leverages MedInformatix RIS as Practice Management Hub, Data Mining Tool to Improve Workflow and Enhance Efficiencies 4CareFusion Announces Departure of Chief Operating Officer 2
Biotest ELPHA (=Enzyme Linked Probe Hybridization Assay) for class I and class II HLA typing shows convincing advantages for your lab routine....
This ELISA test is used for the detection and semi-quantitation of lgG antibobies to proteinase 3(pr3) in human sera, as an aid to the diagnosis of wegener s granulomatosis....
... for the semi-quantitative determination of specific ... serum. The results of the anti-GBM.assay ... in the diagnosis of diseases associated ... including Goodpastures Syndrome. Levels of these ...
The assay is an immunometric ('sandwich') EIA for the quantitative measurement of LH in human serum or plasma. LH in the sample is bound by 2 monoclonal anti-LH antibodies directed at different epito...
Medicine Products: